The importance of resistance to direct antiviral drugs in HCV infection in …

Articles citing The importance of resistance to direct antiviral drugs in HCV infection in …

Title / Author	Year
EASL recommendations on treatment of hepatitis C 2016. European Association for The Study of The Liver Journal of hepatology 66 (1), 153	2017
Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens JM Pawlotsky Gastroenterology 151 (1), 70-86	2016
Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection M Bourlière, SC Gordon, SL Flamm, CL Cooper, A Ramji, M Tong, ... New England Journal of Medicine 376 (22), 2134-2146	2017
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome S Zeuzem, M Mizokami, S Pianko, A Mangia, KH Han, R Martin, ... Journal of hepatology 66 (5), 910-918	2017
The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control J Bukh Journal of hepatology 65 (1), S2-S21	2016
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018 MC Sorbo, V Cento, VC Di Maio, AYM Howe, F Garcia, CF Perno, ... Drug Resistance Updates 37, 17-39	2018
Current therapy for chronic hepatitis C: The role of direct-acting antivirals G Li, E De Clercq Antiviral research 142, 83-122	2017
Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data Z Chen, H Li, H Ren, P Hu Scientific reports 6, 20310	2016
Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals J Dietz, S Susser, J Vermehren, KH Peiffer, G Grammatikos, A Berger, ... Gastroenterology 154 (4), 976-988. e4	2018
Sofosbuvir and ledipasvir for 8 weeks for the treatment of chronic hepatitis C virus (HCV) infection in HCV-monoinfected and HIV-HCV–coinfected individuals: Results from the German Hepatitis C Cohort (GECCO-01) P Ingiliz, S Christensen, T Kimhofer, D Hueppe, T Lutz, K Schewe, ... Clinical infectious diseases 63 (10), 1320-1324	2016
Mechanisms of hepatitis C viral resistance to direct acting antivirals A Ahmed, DJ Felmlee Viruses 7 (12), 6716-6729	2015
Direct‐acting antivirals in hepatitis C virus (HCV)‐infected and HCV/HIV‐coinfected patients: real‐life safety and efficacy L Milazzo, A Lai, E Calvi, P Ronzi, V Micheli, F Binda, AL Ridolfo, ... HIV medicine 18 (4), 284-291	2017
Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein EJ Lawitz, H Dvory-Sobol, BP Doehle, AS Worth, J McNally, DM Brainard, ... Antimicrobial agents and chemotherapy 60 (9), 5368-5378	2016
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: considerations for scientists and funding agencies R Bartenschlager, TF Baumert, J Bukh, M Houghton, SM Lemon, ... Virus research 248, 53-62	2018
Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver International 37 (4), 514-528	2017
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection J Vermehren, JS Park, IM Jacobson, S Zeuzem Journal of Hepatology 69 (5), 1178-1187	2018
Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients LI Backus, PS Belperio, TA Shahoumian, TP Loomis, LA Mole Antivir Ther 22 (6), 481-93	2017
Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir TE Komatsu, S Boyd, A Sherwat, LR Tracy, LK Naeger, JO Julian, ... Gastroenterology 152 (3), 586-597	2017
KASL clinical practice guidelines: management of hepatitis C Korean Association for the Study of the Liver (KASL Clinical and Molecular Hepatology 22 (1), 76	2016
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12 CR Werner, JM Schwarz, DP Egetemeyr, R Beck, NP Malek, UM Lauer, ... World journal of gastroenterology 22 (35), 8050	2016

1 - 20

Dates and citation counts are estimated and are determined automatically by a computer program.